ClinicalTrials.gg
RecruitingNCT06625177Updated Oct 29, 2026

A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

A Phase 1 interventional study of TEV-53408 in Vitiligo, sponsored by Teva Branded Pharmaceutical Products R&D LLC. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Teva Branded Pharmaceutical Products R&D LLC (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Planned enrollment
24th of 68
66 · median 37
Started
2024
with 4 others
Phase 1
5 of 80
1 open now
Primary completion
2028-04
later than 17 of 23 live
Registered
72nd of 80
by date

Among the 80 studies in Vitiligo with a site in United States, this one is the 24th largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 1, reaches primary completion later than 17 of the 23 other live ones, and was the 72nd registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.

03

Conditions studied

  • Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of active or stable vitiligo for at least 3 months.
  • The participant has a (BMI) within the range of 18.5 to 40.0 kg/m2
  • A female participant is eligible if she is not pregnant or breastfeeding AND is a woman of nonchildbearing potential OR is a women of using a method that is highly effective AND agrees not to donate eggs for the purpose of reproduction for the required period
  • A male participant is eligible if he agrees to refrain from donating sperm PLUS remain abstinent from heterosexual intercourse OR use a male condom with a female partner for the required period
  • The participant is capable of giving signed,
  • The participant agrees to discontinue all agents and procedures used to treat vitiligo during the treatment period in the trial
  • If receiving permitted concomitant medications for any reason other than vitiligo, the participant must be on a stable regimen,
  • The participant must agree to avoid prolonged exposure to the sun, must use sunscreen, and must not use tanning booths, sun lamps, or other ultraviolet light sources

NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The participant suffers from vitiligo induced by exposure to chemicals or immunotherapy known to induce vitiligo
  • The participant has other diseases for which systemic immunotherapy is or may be warranted
  • The participant has current or history of or treatment of malignancy in the last 5 years, excluding fully-treated basal cell carcinoma
  • Infectious disease
  • The participant has used skin bleaching treatments for past treatment of vitiligo or other pigmented areas
  • The participant has a history of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. After 2 or more years since last melanocyte-keratinocyte transplantation procedure, the participants may be included in the trial.
  • The participant has donated or received any blood or blood products (white blood cells, , etc) within the 60 days prior to screening or has donated blood or blood products on 2 or more occasions within the 6 months prior to IMP administration, or has donated plasma within 7 days before the screening visit, or has planned donations during the trial
  • The participant has current or history of alcohol or other substance abuse

NOTE- Additional criteria apply, please contact the investigator for more information

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Dose A

    Drug: TEV-53408

  • Experimental
    Cohort 2

    Dose A

    Drug: TEV-53408

  • Experimental
    Cohort 3

    Dose B

    Drug: TEV-53408

Interventions

  • DrugTEV-53408

    TEV-53408 injection administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Treatment-Emergent Adverse Event

    Time frame: Up to Week 40

  2. Number of Participants With at Least One Serious Treatment-Emergent Adverse Event

    Time frame: Up to Week 40

  3. Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest

    Time frame: Up to Week 40

  4. Number of Participants With at Least One Treatment-Related Adverse Event

    Time frame: Up to Week 40

  5. Number of Participants who Discontinued Treatment due to an Adverse Event

    Time frame: Up to Week 40

Secondary outcomes

  1. Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest

    Time frame: Week 40 to Week 80

07

Study locations

7 of 13 sites recruiting
  • Scottsdale Clinical Research
    Scottsdale, Arizona 85260, United States
    Terminated

    Not enrolling at this site.

  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
    Recruiting
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
    Recruiting
  • University of CA Irvine
    Irvine, California 92617, United States
    Active, not recruiting

    Not enrolling at this site.

  • Pasadena Clinical Trials
    Pasadena, California 91101, United States
    Active, not recruiting

    Not enrolling at this site.

  • Watson Therapeutics Inc. (WTI), USA
    Miramar, Florida 33025, United States
    Recruiting
  • MetroMed Clinical Trials
    Chicago, Illinois 60614, United States
    Active, not recruiting

    Not enrolling at this site.

  • DS Research of Kentucky
    Louisville, Kentucky 40421, United States
    Recruiting
  • Hamzavi Dermatology
    Canton, Michigan 48187, United States
    Recruiting
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
    Recruiting
  • Dermatology Treatment & Research Center
    Dallas, Texas 75230, United States
    Recruiting
  • Center for Clinical Studies, LTD. LLP
    Webster, Texas 77598, United States
    Active, not recruiting

    Not enrolling at this site.

  • Jordan Valley Dermatology
    South Jordan, Utah 84095, United States
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Apr 2028, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Apr 26, 2028
CompletionEst.
Jan 31, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 9, 2026
Sites
13 sites added, 13 sites removed. 13 sites changed recruiting status (9 now active, not recruiting, 3 now recruiting, …)
Show 13 sites
  • Teva Investigational Site 12043 · Scottsdale, United Statesno status→Terminated
  • Teva Investigational Site 12052 · Hot Springs, United Statesno status→Recruiting
  • Teva Investigational Site 12044 · Fremont, United Statesno status→Recruiting
  • Teva Investigational Site 12051 · Irvine, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12046 · Pasadena, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12049 · Miramar, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12047 · Chicago, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12053 · Louisville, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12048 · Canton, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12054 · Portland, United Statesno status→Recruiting
  • Teva Investigational Site 12045 · Dallas, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12057 · Webster, United Statesno status→Active, not recruiting
  • Teva Investigational Site 12055 · South Jordan, United Statesno status→Active, not recruiting
Show 13 added (13 United States)
  • Scottsdale Clinical Research · Scottsdale, United States
  • Burke Pharmaceutical Research · Hot Springs, United States
  • Center for Dermatology Clinical Research, Inc. · Fremont, United States
  • University of CA Irvine · Irvine, United States
  • Pasadena Clinical Trials · Pasadena, United States
  • Watson Therapeutics Inc. (WTI), USA · Miramar, United States
  • MetroMed Clinical Trials · Chicago, United States
  • DS Research of Kentucky · Louisville, United States
  • Hamzavi Dermatology · Canton, United States
  • Oregon Dermatology and Research Center · Portland, United States
  • Dermatology Treatment & Research Center · Dallas, United States
  • Center for Clinical Studies, LTD. LLP · Webster, United States
  • Jordan Valley Dermatology · South Jordan, United States
Show 13 removed
  • Teva Investigational Site 12043 · Scottsdale, United States
  • Teva Investigational Site 12052 · Hot Springs, United States
  • Teva Investigational Site 12044 · Fremont, United States
  • Teva Investigational Site 12051 · Irvine, United States
  • Teva Investigational Site 12046 · Pasadena, United States
  • Teva Investigational Site 12049 · Miramar, United States
  • Teva Investigational Site 12047 · Chicago, United States
  • Teva Investigational Site 12053 · Louisville, United States
  • Teva Investigational Site 12048 · Canton, United States
  • Teva Investigational Site 12054 · Portland, United States
  • Teva Investigational Site 12045 · Dallas, United States
  • Teva Investigational Site 12057 · Webster, United States
  • Teva Investigational Site 12055 · South Jordan, United States
across 2 updates, Oct 9, 2026 – Oct 29, 2026
Contact
Study contact now listed: added U•••@tevapharm.com · •••8279. See the current contact
Oct 9, 2026
Show all 2 updates
  1. Oct 29, 2026
    13 sites added, 13 sites removed
    Show 13 added (13 United States)
    • Scottsdale Clinical Research · Scottsdale, United States
    • Burke Pharmaceutical Research · Hot Springs, United States
    • Center for Dermatology Clinical Research, Inc. · Fremont, United States
    • University of CA Irvine · Irvine, United States
    • Pasadena Clinical Trials · Pasadena, United States
    • Watson Therapeutics Inc. (WTI), USA · Miramar, United States
    • MetroMed Clinical Trials · Chicago, United States
    • DS Research of Kentucky · Louisville, United States
    • Hamzavi Dermatology · Canton, United States
    • Oregon Dermatology and Research Center · Portland, United States
    • Dermatology Treatment & Research Center · Dallas, United States
    • Center for Clinical Studies, LTD. LLP · Webster, United States
    • Jordan Valley Dermatology · South Jordan, United States
    Show 13 removed
    • Teva Investigational Site 12043 · Scottsdale, United States
    • Teva Investigational Site 12052 · Hot Springs, United States
    • Teva Investigational Site 12044 · Fremont, United States
    • Teva Investigational Site 12051 · Irvine, United States
    • Teva Investigational Site 12046 · Pasadena, United States
    • Teva Investigational Site 12049 · Miramar, United States
    • Teva Investigational Site 12047 · Chicago, United States
    • Teva Investigational Site 12053 · Louisville, United States
    • Teva Investigational Site 12048 · Canton, United States
    • Teva Investigational Site 12054 · Portland, United States
    • Teva Investigational Site 12045 · Dallas, United States
    • Teva Investigational Site 12057 · Webster, United States
    • Teva Investigational Site 12055 · South Jordan, United States
  2. Oct 9, 2026
    Active, not recruiting→Recruiting
    13 sites changed recruiting status (9 now active, not recruiting, 3 now recruiting, …)
    Show 13 sites
    • Teva Investigational Site 12043 · Scottsdale, United Statesno status→Terminated
    • Teva Investigational Site 12052 · Hot Springs, United Statesno status→Recruiting
    • Teva Investigational Site 12044 · Fremont, United Statesno status→Recruiting
    • Teva Investigational Site 12051 · Irvine, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12046 · Pasadena, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12049 · Miramar, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12047 · Chicago, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12053 · Louisville, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12048 · Canton, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12054 · Portland, United Statesno status→Recruiting
    • Teva Investigational Site 12045 · Dallas, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12057 · Webster, United Statesno status→Active, not recruiting
    • Teva Investigational Site 12055 · South Jordan, United Statesno status→Active, not recruiting
    Contact Study contact now listed: added U•••@tevapharm.com · •••8279. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06625177
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Nov 11, 2024
Primary completion
Apr 26, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Teva U.S. Medical Information
Contact
USMedInfo@tevapharm.com
1-888-483-8279
Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion